MedTrace Logo

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

NCT06305663 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 418

Last updated 2025-06-15

No results posted yet for this study

Summary

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

Conditions

  • Myopia

Interventions

DEVICE

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)

DEVICE

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-29
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06305663 on ClinicalTrials.gov